Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2018-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00006025

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Adult Solid Neoplasm

Interventions: Drug: Erlotinib Hydrochloride
Drug: Irinotecan Hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2024-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00045201

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-22

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00006366

Locations: 🇺🇸
CCOP - Columbus, Columbus, Ohio, United States
🇺🇸
Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇨🇦
Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada

and more 232 locations

Irinotecan in Treating Patients With Colorectal Cancer

Terminated

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-02-16

Lead Sponsor: California Cancer Consortium

Target Recruit Count: 28

Registration Number: NCT00003843

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2009-08-25

Lead Sponsor: Yale University

Target Recruit Count: 28

Registration Number: NCT00004924

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸
Northwestern Connecticut Oncology-Hematology Associates - Torrington, Torrington, Connecticut, United States

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

Phase 2

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-17

Lead Sponsor: University of Washington

Registration Number: NCT00030563

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: cisplatin
Drug: docetaxel
Drug: irinotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 259

Registration Number: NCT00012220

Locations: 🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States

and more 73 locations

Irinotecan in Treating Aging Patients With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: irinotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 140

Registration Number: NCT00026195

Locations: 🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
Vermont Cancer Center, Burlington, Vermont, United States

and more 44 locations

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 22

Registration Number: NCT00006465

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2009-12-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00006485

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy